Application | Comment | Organism |
---|---|---|
medicine | pyrvinium pamoate has an anti-cancer effect within tumour-mimicking microenvironments. Pyrvinium pamoate inhibits NADH-fumarate reductase activities in both parasites and mammalian mitochondria and increases the activity of complex II, succinate-ubiquinone reductase, which is part of fumarate reductase, in mitochondria from human cancer cells cultured under normoxia-normoglycemic conditions but not under hypoxia-hypoglycemic conditions | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
pyrvinium pamoate | anthelmintic, has an anti-cancer effect within tumour-mimicking microenvironments. Pyrvinium pamoate inhibits NADH-fumarate reductase activities in both parasites and mammalian mitochondria and increases the activity of complex II, succinate-ubiquinone reductase, which is part of fumarate reductase, in mitochondria from human cancer cells cultured under normoxia-normoglycemic conditions but not under hypoxia-hypoglycemic conditions | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
mitochondrion | - |
Homo sapiens | 5739 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
DLD-1 cell | under hypoxic-hypoglycemic conditions, NADH-fumarate reductase activity increases, whereas NADH-oxidase activity decreases | Homo sapiens | - |
Hep-G2 cell | under hypoxic-hypoglycemic conditions, NADH-fumarate reductase activity increases, whereas NADH-oxidase activity decreases | Homo sapiens | - |
PANC-1 cell | under hypoxic-hypoglycemic conditions, NADH-fumarate reductase activity increases, whereas NADH-oxidase activity decreases | Homo sapiens | - |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0005 | - |
pH 7.5, 30°C | Homo sapiens | pyrvinium pamoate |